UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Validation of Adapted Neutralization Assays Developed to Discriminate Anti-Rabies Virus Activity of Two Different Anti-Rabies Virus Monoclonal Antibodies Administered as a Combination

Biologics (Basel, Switzerland), 2023-01, Vol.3 (1), p.11-22

2023

Volltextzugriff (PDF)

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

Journal of Virology, 2003-08, Vol.77 (15), p.8263-8271

2003

Volltextzugriff (PDF)

Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity

The Journal of immunology (1950), 2004-05, Vol.172 (10), p.6290-6297

2004

Volltextzugriff (PDF)

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

Journal of Clinical Microbiology, 2003-11, Vol.41 (11), p.5046-5052

2003

Volltextzugriff (PDF)

Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples

Antimicrobial Agents and Chemotherapy, 2012-07, Vol.56 (7), p.3524-3530

2012

Volltextzugriff (PDF)

Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

Journal of Virology, 2004-03, Vol.78 (6), p.2666-2673

2004

Volltextzugriff (PDF)

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

Journal of Virology, 1999-11, Vol.73 (11), p.9153-9160

1999

Volltextzugriff (PDF)

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity

Vaccine, 2004-08, Vol.22 (23), p.3035-3044

2004

Volltextzugriff (PDF)

Evidence that human CD8+CD45RA+CD27– cells are induced by antigen and evolve through extensive rounds of division

International immunology, 1999-07, Vol.11 (7), p.1027-1033

1999

Volltextzugriff (PDF)

A Peptide-Based Plasmodium falciparum Circumsporozoite Assay To Test for Serum Antibody Responses to Pre-Erythrocyte Malaria Vaccines

Clinical and Vaccine Immunology, 2011-05, Vol.18 (5), p.776-782

2011

Volltextzugriff (PDF)

Comparison of Human Primary microglia and Human iPSC derived microglia cells as in vitro models for microglia activation

Alzheimer's & dementia, 2023-12, Vol.19 (S13)

2023

Volltextzugriff (PDF)

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

Pharmaceutical research, 2013-07, Vol.30 (7), p.1719-1728

2013

Volltextzugriff (PDF)

37-OR: Childhood Screening and Interception Strategies: An Economic Cohort Simulation Model

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Challenges of immunogenicity assays for vaccines

Bioanalysis, 2012-02, Vol.4 (4), p.397-406

2012

Volltextzugriff (PDF)

HIV-specific CD8 + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

Nature immunology, 2002-11, Vol.3 (11), p.1061-1068

2002

Volltextzugriff (PDF)

A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective

Journal of immunological methods, 2015-02, Vol.417, p.1-9

2015

Volltextzugriff (PDF)

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

AIDS (London), 2004-05, Vol.18 (8), p.1213-1216

2004

Volltextzugriff (PDF)

Induction of CAMEL NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5 35 fiber

Cancer gene therapy, 2004-03, Vol.11 (3), p.227-236

2004

Volltextzugriff (PDF)

Persistent numbers of tetramer+ CD8+ T cells, but loss of interferon-γ+ HIV-specific T cells during progression to AIDS

Blood, 2002-04, Vol.99 (7), p.2505-2511

2002

Volltextzugriff (PDF)

Failing immune control as a result of impaired CD8 + T-cell maturation: CD27 might provide a clue

Trends in immunology, 2002-12, Vol.23 (12), p.586-591

2002

Volltextzugriff (PDF)

Stability studies of binding and functional anti-vaccine antibodies

Bioanalysis, 2014-05, Vol.6 (10), p.1385-1393

2014

Volltextzugriff (PDF)

High viral burden in the presence of major HIV‐specific CD8+ T cell expansions: evidence for impaired CTL effector function

European journal of immunology, 2001-03, Vol.31 (3), p.677-686

2001

Volltextzugriff (PDF)

Dysfunctional Epstein-Barr virus (EBV)–specific CD8+T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma

Blood, 2001-07, Vol.98 (1), p.146-155

2001

Volltextzugriff (PDF)

Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection

AIDS (London), 2002-10, Vol.16 (15), p.2001-2011

2002

Volltextzugriff (PDF)

Characterization of virus-specific CD8 + effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors

Clinical immunology (Orlando, Fla.), 2004-12, Vol.113 (3), p.299-309

2004

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(25)
Immunology
(15)
Biological And Medical Sciences
(13)
Cd8-Positive T-Lymphocytes - Immunology
(12)
Hiv Infections - Immunology
(12)
Virology
(11)
Medical Sciences
(10)
Infectious Diseases
(9)
Disease Progression
(8)
Hiv-1 - Immunology
(8)
Animals
(7)
Hiv Infections - Virology
(7)
Viral Load
(7)
Aids/hiv
(6)
Hiv
(6)
Adult
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Human Immunodeficiency Virus 1
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Aids
(5)
European Journal Of Immunology
(3)
Journal Of Virology
(3)
Bioanalysis
(2)
Blood
(2)
Trends In Immunology
(2)
Alzheimer's & Dementia
(1)
Antimicrobial Agents And Chemotherapy
(1)
Antiviral Research
(1)
Aquatic Toxicology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation of Adapted Neutralization Assays Developed to Discriminate Anti-Rabies Virus Activity of Two Different Anti-Rabies Virus Monoclonal Antibodies Administered as a Combination

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples

Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity

Evidence that human CD8+CD45RA+CD27– cells are induced by antigen and evolve through extensive rounds of division

A Peptide-Based Plasmodium falciparum Circumsporozoite Assay To Test for Serum Antibody Responses to Pre-Erythrocyte Malaria Vaccines

Comparison of Human Primary microglia and Human iPSC derived microglia cells as in vitro models for microglia activation

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

37-OR: Childhood Screening and Interception Strategies: An Economic Cohort Simulation Model

Challenges of immunogenicity assays for vaccines

HIV-specific CD8 + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

Induction of CAMEL NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5 35 fiber

Persistent numbers of tetramer+ CD8+ T cells, but loss of interferon-γ+ HIV-specific T cells during progression to AIDS

Failing immune control as a result of impaired CD8 + T-cell maturation: CD27 might provide a clue

Stability studies of binding and functional anti-vaccine antibodies

High viral burden in the presence of major HIV‐specific CD8+ T cell expansions: evidence for impaired CTL effector function

Dysfunctional Epstein-Barr virus (EBV)–specific CD8+T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma

Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection

Characterization of virus-specific CD8 + effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors

Suchergebnisse filtern